Navigation Links
OncoMed Pharmaceuticals Completes Series B Financing
Date:11/4/2008

ors. OMP-21M18 targets a major cancer stem cell pathway, and is a part of OncoMed's collaboration with GlaxoSmithKline. The Phase I clinical trial is designed to evaluate the safety of escalating doses of OMP-21M18 in patients with solid tumors who have received previous treatment. Pharmacokinetics and initial indications of efficacy will also be assessed. OMP-21M18 is the first anti-cancer stem cell antibody against this novel target critical to cancer stem cells growth and development.

Cancer stem cells, a small subset of cells found in tumors, have the capacity to self-renew and differentiate, initiate and drive tumor growth, recurrence and metastasis. Also termed "tumor-initiating cells", these cells were discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumors including: colon, head and neck, lung, prostate, glioblastoma and pancreatic. Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy. OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways critical for the activity and survival of cancer stem cells. OncoMed's antibodies targeting cancer stem cell proteins have the potential to be developed against a range of solid tumor types such as pancreatic, breast, colorectal and lung cancers.

In conjunction with the financing, Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures, will join OncoMed's Board of Directors.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal a
'/>"/>

SOURCE OncoMed Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Genesis Pharmaceuticals Launches New Corporate Website
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
11. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 The prestigious "Discovery or ... was recently awarded to Juliana Hillis and Kaylie O’Connell, ... their project, “From an Egg, Everything: America’s First IVF ... entries for the National History Day program during a ... and educators in Washington, D.C. , The growing popularity ...
(Date:7/29/2014)... Sunnyvale, CA (PRWEB) July 29, 2014 ... for medical devices, and cloud based eClinical technologies, have ... Med Device Online. These follow a long line of ... high profile publications including Life Science Leader, Pharmaceutical Online, ... Basics Clinovo provided a paper by CTO Marc Desgrousilliers, ...
(Date:7/29/2014)... , July 29, 2014 ... Biopsy System (LBS) zur Erfassung biologischer Daten ... Herzkranzgefäßen entwickelt und patentiert. Das LBS nimmt ... der Koronararterie des Patienten und sucht erhöhte ... hat das Potenzial, die Entdeckung und Entwicklung ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... NEWARK, N.J., June 25 BioNeutral announced today ... sell its advanced,chemical technology products to the military, ... have reviewed the test,results announced by Dr. Tierno, ... and Dr Tierno and the performance of the,company,s ...
... Provide 180-Day Marketing Exclusivity Upon ... ... announced today that the company has received tentative approval,from the U.S. ... mg. Total annual market sales for,Valganciclovir HCl Tablets were $239 million ...
... paper titled “Avanta AC™ Advanced Ceramics Solutions ... This white paper outlines the challenges in ... scale, as well as the advantages of ... nanopowders are critical to a variety of ...
Cached Biology Technology:BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs 2Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2
(Date:7/29/2014)... A ground breaking new book that brings together two ... to raise the profile of insect fossils through stunning ... David Penney and James E Jepson, details the incredible ... world, setting the scene for what these remarkable fossils ... and even the future of our planet. Like the ...
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... in 1911, but new research shows that industrial air ... from 16 ice cores collected from widely spaced locations ... group led by Joe McConnell of the Desert Research ... and precise reconstruction to date of lead pollution over ... article published today in the online edition of the ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... Research from the University of California, San Diego ... compulsive behavior and cognitive defects associated with a ... Two pathways found to be defective in LND ... disease, such as Alzheimer,s and Parknson,s diseases, suggesting ...
... evolution. In today,s issue of the journal Science ... that the reverse is also true, and explores what ... change affects species and vice-versa. A classic example ... ground finch, Geospiza fortis. In this species, larger beaks ...
... to a statistically significant level to their sons, and the ... mother smokes it does not seem to impact on the ... smokes does not affect his daughter", Loureiro, a researcher at ... co-author of the study, tells SINC. The research, which ...
Cached Biology News:Genetic clues to compulsive, self-injurious behavior in rare childhood disorder 2Genetic clues to compulsive, self-injurious behavior in rare childhood disorder 3Smoking habits are transmitted from mother to daughter and father to son 2
chk 1 kinase...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
GM130 Immunogen: Recombinant purified rat GM130 Family / Subclass 1: Signal Transduction Storage: 4 C...
Biology Products: